This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
ZIRABEV® (bevacizumab-bvzr) is a biosimilar to Avastin® (bevacizumab) and part of the largest oncology biosimilars portfolio, brought to you by Pfizer
ZIRABEV® (bevacizumab-bvzr) is a biosimilar to Avastin® (bevacizumab) and part of the largest oncology biosimilars portfolio, brought to you by Pfizer
With an identical dosing and administration schedule to Avastin®1
Downloadable resources to help support your implementation of ZIRABEV
With 15+ years of biosimilars experience globally, including more than 1.3 million people treated around the world2,8
View reimbursement, educational, and patient materials
Find videos and on-demand webinars
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.